Literature DB >> 8195590

Chemical synthesis of bispecific monoclonal antibodies: potential advantages in immunoassay systems.

A G Cook1, P J Wood.   

Abstract

To date, the applications of bispecific antibodies in immunoassay and immunocytochemical procedures have been directed at uniting two different biomolecules through the binding of epitopes on each respective substance. In this study, bispecific antibodies were constructed in which both binding sites were directed to two different epitopes of the same target molecule. Two types of bispecific antibody were constructed; a bivalent bispecific monoclonal antibody and multivalent bispecific polymers. The binding characteristics of each were investigated for changes in specificity and binding strength relative to 1:1 mixtures of parent antibodies. A bivalent bispecific antibody (BBA) was synthesised by the method of Glennie et al. (1985) from monoclonal antibodies recognising the 'M' or 'B' units of creatine kinase (CKMB). The BBA had enhanced specificity for CKMB with diminished recognition of CKMM and CKBB. A less tedious method of producing bispecific antibody involving heterobifunctional cross-linkage was used to produce multivalent bispecific antibodies (MBAs). Certain MBAs constructed to bind 'M' and 'B' units of CKMB demonstrated enhanced specificity and affinity for CKMB. MBAs were also produced to opposite ends of the 39 amino acid peptide adrenocorticotrophic hormone (ACTH). One of these demonstrated an enhanced affinity of 41-fold. We conclude that while conventional synthesis of bispecific bivalent antibodies is not a practical proposition for immunoassay development, antibodies with similar advantages can be produced with a simple method using the heterobifunctional cross-linker. The production of certain bispecific antibody combinations appears to enhance the formation of antibody-antigen matrices conferring higher binding affinities than can be achieved with an antibody mixture alone.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8195590     DOI: 10.1016/0022-1759(94)90042-6

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  1 in total

1.  Production of stable bispecific IgG1 by controlled Fab-arm exchange: scalability from bench to large-scale manufacturing by application of standard approaches.

Authors:  Michael J Gramer; Ewald T J van den Bremer; Muriel D van Kampen; Amitava Kundu; Peter Kopfmann; Eric Etter; David Stinehelfer; Justin Long; Tom Lannom; Esther H Noordergraaf; Jolanda Gerritsen; Aran F Labrijn; Janine Schuurman; Patrick H C van Berkel; Paul W H I Parren
Journal:  MAbs       Date:  2013-08-22       Impact factor: 5.857

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.